Event-Driven Stocks

OptiNose, Inc.

OPTN

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 6 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue$78.2M$71.0M$76.3M$74.7M$49.1M$34.6M
Operating income−$16.3M−$22.7M−$55.9M−$66.5M−$87.2M−$95.6M
Net income−$21.5M−$35.5M−$74.8M−$82.3M−$99.8M−$110.1M
Total assets$128.8M$107.7M$144.2M$166.1M$188.8M$172.7M
Total liabilities$169.1M$194.3M$200.8M$187.8M$182.0M$111.1M
Equity−$40.4M−$86.6M−$56.6M−$21.8M$6.8M$61.6M
EPS (diluted)$-2.12$-4.75$-0.87$-1.45$-2.07—
Shares out.112.7M111.8M82.4M52.9M45.9M41.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
−20.9%
Net margin
−27.5%
Return on equity
53.4%
Return on assets
−16.7%
Return on capital (ROCE)
—
Liabilities / assets
131.3%
Debt / equity
—
Book value / share
$-0.36
Revenue growth (YoY)
10.2%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
-21.77distress
Accruals / assets
18.0%high accruals
Beneish M-Score
-1.18elevated
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
32
/ 100
Profitability 25Growth 100Catalyst 33Earnings quality 0Financial strength 0

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 6 warning● 2 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2025130,6218.4-1.5%
Apr 30, 2025132,6514.6-6.7%
Apr 15, 2025142,2071.0-25.8%
Mar 31, 2025191,7351.0-29.4%
Mar 14, 2025271,74712.8+11.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)